dc.contributor.author | Malek Mahdavi, A | |
dc.contributor.author | Mahdavi, R | |
dc.contributor.author | Kolahi, S | |
dc.date.accessioned | 2018-08-26T08:53:27Z | |
dc.date.available | 2018-08-26T08:53:27Z | |
dc.date.issued | 2016 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/53952 | |
dc.description.abstract | Objective: Considering the importance of inflammation in the pathogenesis of osteoarthritis (OA) and induction of pain, this study was aimed to investigate the effect of L-carnitine supplementation on serum inflammatory mediators and OA-associated pain in females with knee OA. Methods: In this clinical trial, 72 females with mild to moderate knee osteoarthritis started the study, divided into 2 groups to receive 750 mg/day L-carnitine (n = 36) or placebo (n = 36) for 8 weeks. Serum levels of Interleukine-1? (IL-1?), high-sensitivity C-reactive protein (hs-CRP), matrix metalloproteinases (MMPs)-1 and -13, and visual analog scale (VAS) for pain were assessed before and after supplementation. Data were analyzed by t test, Wilcoxon signed rank test, Mann-Whitney U test, and analysis of covariance. Results: Only 69 patients (33 in the L-carnitine group and 36 in the placebo group) completed the study. L-Carnitine supplementation decreased serum IL-1? and MMP-1 levels significantly (p = 0.001 and p = 0.021, respectively); however, serum hs-CRP and MMP-13 levels did not change significantly (p > 0.05). In the placebo group, serum IL-1? levels increased significantly (p = 0.011), whereas other studied biomarkers did not change significantly. The mean VAS score decreased significantly in the L-carnitine and placebo groups by 52.67% and 21.82%, respectively (p < 0.001). Significant differences were only observed between the 2 groups in serum IL-1? (p < 0.001) and MMP-1 (p = 0.006) levels and mean VAS score (p = 0.002) after adjusting for baseline values and covariates. Conclusion: Despite observed beneficial effects of short-term supplementation of L-carnitine in decreasing serum inflammatory mediators and improving pain in knee OA patients, further studies are needed to achieve concise conclusions. © 2016, © American College of Nutrition Published by Taylor & Francis Group, LLC. | |
dc.language.iso | English | |
dc.relation.ispartof | Journal of the American College of Nutrition | |
dc.subject | C reactive protein | |
dc.subject | carnitine | |
dc.subject | collagenase 3 | |
dc.subject | interleukin 1beta | |
dc.subject | interstitial collagenase | |
dc.subject | placebo | |
dc.subject | antiinflammatory agent | |
dc.subject | biological marker | |
dc.subject | C reactive protein | |
dc.subject | carnitine | |
dc.subject | collagenase 3 | |
dc.subject | interleukin 1beta | |
dc.subject | interstitial collagenase | |
dc.subject | matrix metalloproteinase | |
dc.subject | adult | |
dc.subject | Article | |
dc.subject | biochemical analysis | |
dc.subject | body mass | |
dc.subject | body weight | |
dc.subject | caloric intake | |
dc.subject | controlled study | |
dc.subject | diet supplementation | |
dc.subject | disease severity assessment | |
dc.subject | double blind procedure | |
dc.subject | enzyme linked immunosorbent assay | |
dc.subject | female | |
dc.subject | human | |
dc.subject | inflammation | |
dc.subject | knee osteoarthritis | |
dc.subject | major clinical study | |
dc.subject | pain severity | |
dc.subject | randomized controlled trial | |
dc.subject | turbidimetry | |
dc.subject | visual analog scale | |
dc.subject | blood | |
dc.subject | dietary supplement | |
dc.subject | inflammation | |
dc.subject | middle aged | |
dc.subject | Osteoarthritis, Knee | |
dc.subject | pilot study | |
dc.subject | Anti-Inflammatory Agents | |
dc.subject | Biomarkers | |
dc.subject | C-Reactive Protein | |
dc.subject | Carnitine | |
dc.subject | Dietary Supplements | |
dc.subject | Double-Blind Method | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Inflammation | |
dc.subject | Interleukin-1beta | |
dc.subject | Matrix Metalloproteinase 1 | |
dc.subject | Matrix Metalloproteinase 13 | |
dc.subject | Matrix Metalloproteinases | |
dc.subject | Middle Aged | |
dc.subject | Osteoarthritis, Knee | |
dc.subject | Pilot Projects | |
dc.subject | Placebos | |
dc.title | Effects of l-Carnitine Supplementation on Serum Inflammatory Factors and Matrix Metalloproteinase Enzymes in Females with Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Pilot Study | |
dc.type | Article | |
dc.citation.volume | 35 | |
dc.citation.issue | 7 | |
dc.citation.spage | 597 | |
dc.citation.epage | 603 | |
dc.citation.index | Scopus | |
dc.identifier.DOI | https://doi.org/10.1080/07315724.2015.1068139 | |